Higher levels of oxidative stress in males results in lower levels of a cofactor needed to make the powerful blood vessel dilator nitric oxide, researchers report.
Dr. Jennifer C. Sullivan, Augusta University. (Image Credit: Phil Jones, Senior Photographer, Augusta University)
An antioxidant appears to help level the playing field between males and females of the cofactor BH deep inside the kidneys - where the fine-tuning of our blood pressure happens - and restore similar production levels of protective nitric oxide.
Higher nitric oxide levels help reduce blood pressure both by enabling dilation of blood vessels and increasing the kidneys' excretion of sodium, which decreases the volume in those blood vessels.
"We found that oxidative stress makes a big difference in BH levels." said Dr. Jennifer C. Sullivan, pharmacologist and physiologist in the Department of Physiology at the Medical College of Georgia at Augusta University, who is exploring gender differences in hypertension.
The study in the journal Bioscience Reports is the first to look at sex differences of BH in a rodent model of hypertension.
Male humans generally have higher blood pressures and oxidative stress levels than females, at least until menopause. The findings provide more evidence that the cofactor might be a novel treatment target for both sexes, says Sullivan, the study's corresponding author.
Tetrahydrobiopterin, is required for the precursor nitric oxide synthase to make nitric oxide.
Oxidative stress, which results from high levels of natural byproducts of oxygen use, is known to reduce BH levels, is implicated in high blood pressure and, at least before menopause, females tend to be less sensitive to it, possibly because of the protective effects of estrogen.
In an attempt to figure out why females, even in the face of hypertension, have more nitric oxide, the scientists measured BH levels in the inner most part of the kidney in male and female spontaneously hypertensive rats.
"We found BH levels were higher in the hypertensive females than the hypertensive males," Sullivan says. Females also had more nitric oxide and lower - but still high - blood pressures, and the males had more oxidative stress.
They had previously shown that young spontaneously hypertensive female rats have significantly more nitric oxide and nitric oxide synthase activity in the inner portion of their kidney than their male hypertensive counterparts, and that difference holds as the rats mature. The new work helps explain why.
If we don't understand why females have more nitric oxide, we can't do things to potentiate our ability to make it."
Jennifer C. Sullivan
The scientists theorized - and found - that the elevated levels of oxidative stress in the males meant less BH, and ultimately less nitric oxide compared to females.
They found that reducing oxidative stress improved BH?, levels and nitric oxide production and "normalized the playing fields between the two sexes," Sullivan says.
Without BH, nitric oxide synthase becomes "uncoupled" and instead produces superoxide, which decreases nitric oxide production but also interacts with the nitric oxide that is available to form the oxidant peroxynitrite.
Destructive peroxynitrite, in turn, targets the BH that is present so it becomes BH, which further interferes with BH's normal job of helping nitric oxide synthase make nitric oxide.
"You don't make the product you want nitric oxide synthase to make, which is nitric oxide," Sullivan says.
While it's not clear that females are any better of making BH, it is clear that the cofactor is easily altered by oxidative stress to become its unhealthy counterpart BH, Sullivan says.
Giving both males and females the synthetic antioxidant treatment Tempol for two weeks is what leveled the gender field.
Bottom line: the antioxidant treatment essentially eliminated the sex differences in BH and nitric oxide synthase activity in that key region of the kidneys.
Males had a higher blood pressure at baseline and the antioxidant treatment had no effect on the blood pressure of either sex.
More work is needed to explore BH's treatment potential in both sexes, Sullivan says.
BH is widely available without a prescription, and its impact has been evaluated in a number of clinical trials including a current study at the University of Nebraska, Omaha, looking at its effect on blood flow and exercise capacity in patients with peripheral artery disease.
Study coauthors Dr. David G. Harrison, director of the Division of Clinical Pharmacology at Vanderbilt University Medical Center, and Dr. Wei Chen, research associate in the division, measured BH levels in the rat kidneys.
The research was supported by the National Institutes of Health and the American Heart Association.